Corporate Events

Sawai Group Holdings Co., Ltd.(TSE:4887) dropped from FTSE All-World Index (USD)

IR Day 2026

Sawai Group Holdings Co., Ltd. provided consolidated earnings guidance for the fiscal year ending March 31, 2027. For the year, the company expects revenue of JPY 208,400 million, operating profit of JPY 27,200 million, Profit attributable to owners of parent of JPY 18,600 million and basic earnings per share of JPY 161.08.

Sawai Group Holdings Co., Ltd. reported earnings results for the first quarter ended June 30, 2026. For the first quarter, the company reported sales was JPY 51,622 million compared to JPY 49,511 million a year ago. Net income was JPY 2,429 million compared to JPY 4,891 million a year ago. Basic earnings per share from continuing operations was JPY 24.79 compared to JPY 42.06 a year ago. Diluted earnings per share from continuing operations was JPY 24.71 compared to JPY 41.92 a year ago. Basic earnings per share was JPY 21.04 compared to JPY 42.36 a year ago. Diluted earnings per share was JPY 20.97 compared to JPY 42.22 a year ago.

Sawai Group Holdings Co., Ltd., Q1 2027 Earnings Call, Aug 10, 2026

Sawai Group Holdings Co., Ltd. has announced a Fixed-Income Offering. Security Name: Straight Bonds due July 30, 2036 Security Type: Corporate Bond/Note (Non Convertible) Principal Amount: ¥10 billion Security Features: Unsecured

Sawai Group Holdings Co., Ltd., ¥ 28.0, Cash Dividend, Sep-29-2026

Sawai Group Holdings Co., Ltd., Board Meeting, Jun 25, 2026. Agenda: To consider and approve the Issuance of New Shares as Restricted Share Compensation and Performance-linked Restricted Share Compensation.

Sawai Group Holdings Co., Ltd. proposed at its AGM to be held on June 25, 2026 a dividend for the Fiscal year ended March 31, 2026 of JPY 28.00 per share against a dividend of JPY 27.00 per share a year ago. Payable on June 26, 2026. The company, provided dividend guidance for the second quarter end of Fiscal year ending March 31, 2027 of JPY 28.00 per share against dividend of JPY 27.00 a year ago.

Sawai Group Holdings Co., Ltd. provided dividend guidance for Fiscal year ending March 31, 2027 of JPY 28.00 per share against JPY 28.00 per share a year ago.

Sawai Group Holdings Co., Ltd. provided consolidated earnings guidance for the six months ending September 30, 2026 and fiscal year ending March 31, 2027. For the six months, the company expects revenue of JPY 101,000 million, operating profit of JPY 13,100 million, Profit attributable to owners of parent of JPY 8,900 million and basic earnings per share of JPY 77.08. For the year, the company expects revenue of JPY 208,400 million, operating profit of JPY 27,200 million, Profit attributable to owners of parent of JPY 18,600 million and basic earnings per share of JPY 161.09.

Sawai Group Holdings Co., Ltd. announced that they will report Q1, 2027 results at 1:00 PM, Tokyo Standard Time on Aug 10, 2026

Sawai Group Holdings Co., Ltd., Board Meeting, May 22, 2026. Agenda: To conduct Absorption-type Merger between Wholly Owned Subsidiaries.

Sawai Group Holdings Co., Ltd. expected to report Q1 2027 results on August 13, 2026. This event was calculated by S&P Global (Created on May 21, 2026).

Sawai Group Holdings Co., Ltd., Annual General Meeting, Jun 25, 2026, at 10:00 Tokyo Standard Time. Location: 10th Floor Hall, Head Office SAWAI GROUP HOLDINGS Co., Ltd. 5-2-30 Miyahara, Yodogawa-ku, Osaka Japan Agenda: To consider business report and consolidated financial statements for the 5th fiscal year from April 1, 2025 to March 31, 2026 as well as the report of the results of audits by the accounting auditor and audit & supervisory committee on such consolidated financial statements; to consider non-consolidated financial statements for the 5th fiscal year from April 1, 2025 to March 31, 2026; and to consider other matters.

Sawai Group Holdings Co., Ltd., 2026 Earnings Call, May 19, 2026

Sawai Group Holdings Co., Ltd., Board Meeting, Mar 05, 2026. Agenda: to implement personnel changes in the Representative Directors and Corporate Officers of Sawai Pharmaceutical Co., Ltd. (hereinafter "Sawai Pharmaceutical"), a consolidated subsidiary of the Company.

Sawai Group Holdings Co., Ltd. has completed a Fixed-Income Offering in the amount of ¥7.5 billion. Security Name: Notes due December 11, 2030 Security Type: Corporate Bond/Note (Non Convertible) Principal Amount: ¥7.5 billion Price\Range: 100% Security Features: Unsecured

Sawai Group Holdings Co., Ltd. announced that they will report fiscal year 2026 results at 3:00 PM, Tokyo Standard Time on May 15, 2026

Sawai Group Holdings Co., Ltd. reported earnings results for the nine months ended December 31, 2025. For the nine months, the company reported sales was JPY 154,864 million compared to JPY 143,208 million a year ago. Net income was JPY 10,749 million compared to JPY 25,456 million a year ago. Basic earnings per share from continuing operations was JPY 94.24 compared to JPY 113.11 a year ago. Diluted earnings per share from continuing operations was JPY 93.94 compared to JPY 112.77 a year ago. Basic earnings per share was JPY 93.09 compared to JPY 201.29 a year ago. Diluted earnings per share was JPY 92.79 compared to JPY 200.69 a year ago.

Sawai Group Holdings Co., Ltd., Q3 2026 Earnings Call, Feb 13, 2026

Sawai Group Holdings Co., Ltd. expected to report Fiscal Year 2026 results on May 11, 2026. This event was calculated by S&P Global (Created on February 13, 2026).

Sawai Group Holdings Co., Ltd. announced dividend of JPY 27.00 per share for the second quarter ended September 30, 2025 compared to JPY 78.00 per share paid a year ago. Scheduled date to commence dividend payments: December 1, 2025.

Sawai Group Holdings Co., Ltd. announced that they will report Q3, 2026 results at 1:00 PM, Tokyo Standard Time on Feb 13, 2026

Sawai Group Holdings Co., Ltd. revised consolidated earnings guidance for the first half ended September 30, 2025 and the full year ending March 31, 2026. For the first half, Company now expects revenue of JPY 98,800 million, operating profit of JPY 8,500 million, profit attributable to owners of parent of JPY 5,800 million and basic earnings per share of JPY 50.23 against previous guidance of revenue of JPY 96,500 million, operating profit of JPY 13,200 million, profit attributable to owners of parent of JPY 9,000 million and basic earnings per share of JPY 77.95. For the full year, the company expects revenue of JPY 202,500 million, operating profit of JPY 20,900 million, profit attributable to owners of parent of JPY 14,000 million and basic earnings per share of JPY 121.25 against previous guidance of revenue of JPY 200,200 million, operating profit of JPY 25,600 million, profit attributable to owners of parent of JPY 17,400 million and basic earnings per share of JPY 150.71. Reasons for the Revisions: As stated in the "Notice Regarding Settlement of Lawsuit" dated October 21, 2025, a settlement was reached regarding the patent infringement lawsuit concerning Teriparatide Subcutaneous Injection 56.5g "Sawai." Following the assessment of the impact on the consolidated financial results for the fiscal year ending March 31, 2026, the Company decided to revise the financial results forecasts.

Sawai Group Holdings Co., Ltd., ¥ 28.0, Cash Dividend, Mar-30-2026

Sawai Group Holdings Co., Ltd. expected to report Q3 2026 results on February 13, 2026. This event was calculated by S&P Global (Created on November 14, 2025).

Sawai Group Holdings Co., Ltd., Q2 2026 Earnings Call, Nov 18, 2025

Sawai Group Holdings Co., Ltd. announced that Sawai Pharmaceutical Co., Ltd. has reached a settlement dated October 20, 2025, with Asahi Kasei Pharma Corporation regarding a patent infringement lawsuit concerning TERIPARATIDE for Subcutaneous Injection 56.5ug. Sawai Pharmaceutical had been requested by Asahi Kasei Pharma to cease the manufacturing and sale of its generic teriparatide product and to pay damages for patent infringement, based on the process patent (Patent No. 6025881) related to Teribone 56.5 ug for subcutaneous injection. Sawai Pharmaceutical's claim was not upheld, and on September 26, 2024, The Osaka District Court issued an order preventing the manufacture and sale of the product using the patented method in question and requiring the payment of damages. An appeal was filed with the Intellectual Property High Court of Japan (hereinafter the "IP High Court") against this ruling; however, after carefully considering the overall terms of the settlement, Sawai Pharmaceutical determined that resolving the matter through settlement was a reasonable course of action and reached an agreement accordingly. Sawai Pharmaceutical paid Asahi Kasei Pharma JPY 4 billion yen as a settlement, and Asahi Kasei Pharma waived any other claims against Sawai Pharmaceutical. Details of the settlement will not be disclosed due to confidentiality obligations contained in the settlement terms.